The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.
We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $65.41 as of October 15th.
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
Hunterbrook asserted that some doctors stopped prescribing the G7 due to "disproportionate sensor inaccuracies, repeated ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The FDA approves ...
Dexcom’s technology consists of a sensor – usually worn on the abdomen – that reads glucose levels just beneath the skin. A transmitter sends the data to a smartphone, which processes and displays ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback